Skip to main content
. 2020 Jul 8;8(3):366. doi: 10.3390/vaccines8030366

Figure 4.

Figure 4

Impact of prophylactic HSV-2 vaccination administered to adolescents aged 10–14 years (adolescents’ vaccination) on HSV-2 infection measures in the population aged ≥15 years. Impact of the prophylactic vaccine on (A) annual number of new HSV-2 infections, (B) annual number of HSV-2 infections averted, (C) HSV-2 incidence rate, and (D) HSV-2 seroprevalence, among those aged ≥15 years. The prophylactic vaccine is introduced in 2020, with its coverage scaled up to 80% by 2030, and maintained at this level thereafter. Duration of vaccine-induced protection is 20 years and VES is 50%.